

Development of an acetylcholinesterase biochemical assay using the SCIEX Echo[®] MS system

Chloe Tayler and Amy Burton GSK, UK

Introduction

Biochemical assays are frequently used in drug discovery to monitor enzyme activity and drug potency. These assays are of particular importance in the assessment of potential safety liabilities of new drug candidates. The accurate and timely reporting of these data is critical for decision making within pharmaceutical research. In recent years, mass spectrometry (MS) has presented itself as an attractive detection method for enzyme target screening. It is a label-free technology that allows direct quantification of native substrates and their respective products. Here, the SCIEX Echo MS system was used as a detection technique for a routine acetylcholinesterase (AChE) biochemical safety assay.

AChE is a serine protease that hydrolyses the neurotransmitter acetylcholine (ACh) to choline (Ch) and acetic acid as shown in Figure 1.



Figure 1. The hydrolysis of acetylcholine

AChE is found mainly at neuromuscular junctions and cholinergic brain synapses, where its activity serves to maintain a very low concentration of ACh in the synaptic cleft. Inhibition of AChE leads to an accumulation of ACh in the synaptic cleft, consequently overstimulating the receptors and impeding

Table 1. Comparison of Echo MS system and on-line SPE method parameters for the AChE biochemical assay

	Echo MS system	On-line SPE
Sample analysis time (384 well plate)	~2 seconds (10 mins per plate)	14 seconds (90 mins per plate)
Flow Rates	0.65 mL/min	1-1.5 mL/min
ESI source temperature	e 300 °C	650 °C
Carrier Solvent	0.1% ammonium acetate and 0.1% TFA in acetonitrile	70% acetonitrile with 0.1% formic acid
Injection Volume	2.5 nL	30-40 μL

neurotransmission [1]. While therapeutically beneficial in some cases, this can also lead to adverse effects. Mode-of-action is also important, as irreversible inhibitors can cause high blood pressure, decreased heart rate, bronchoconstriction, and in worst cases, death [2]. Given the potential toxicological effects caused by AChE inhibition, *in vitro* AChE inhibition assays are an important element in the identification of potential safety liabilities. Data from these assays can also be used to develop predictive models when dealing with large chemical libraries [3].

A mass spectrometry (MS)-based *in vitro* assay to measure AChE inhibition had previously been developed at GSK. The assay utilized on-line solid-phase extraction (SPE) to provide effective sample clean up prior to MS injection. The optimized method yielded a 14 second-per-well cycle time that resulted in 90 minutes per 384-well plate. The assay required extra washes between wells to minimize sample carryover. We recently migrated the assay to the SCIEX Echo MS system, which utilizes Acoustic Droplet Ejection and an Open Port Interface (ADE-OPI) coupled to the SCIEX Triple Quad 6500+ mass spectrometer. The Echo MS system assay exhibited excellent sensitivity linearity and reproducibility and runs in under 2 seconds per well or 10 minutes per 384-well plate. A comparison of the two methods is shown in Table 1.

Key features of the Echo MS system for biochemical assay development

- Total analysis time for a 384-well plate is 10 minutes
- Excellent reproducibility of results and minimal carryover in assay buffer conditions
- Low-nM limits of detection and a linear dynamic range exceeding 30 µM for the AChE assay
- User-friendly method development using SCIEX OS software, minimal sample volume requirement during optimization and no requirement for multiple carrier solvent systems



Methods

Determination of analyte linearity and carryover on the Echo MS system

Standard curves for both ACh and Ch were generated using purchased standards starting at a top concentration of 30 μ M. A 2-fold serial dilution series with 15 different concentrations were prepared with 14 mM Tris(hydroxymethyl)aminomethane hydrochloride (Tris HCl) and 0.8% formic acid in LC-MS grade water (to reflect final plate conditions). Data were fitted using linear regression, and analyte limits of detection (LoDs) were calculated using the equation below. Carryover was determined by measuring analyte response in the first blank after the top standard sample had been run.

 $LoD = Mean + (3 \times Standard Deviation) of blank sample$

Determination of apparent K_M for AChE

To determine the Michaelis-Menten parameters for AChE, an ACh titration time course was performed from 1 mM with a 2-fold serial dilution to provide a total of 15 different concentrations. The final reaction mixture (10 μ L) also contained 100 mM Tris HCl, 0.1% DMSO(to mimic compound addition) and 300 pM of AChE. The reaction mixture was incubated at room temperature for 5.5 minutes, with regular quenching taking place every 30 seconds with 40 μ L of 1% formic acid in LC-MS grade water.

Determination of enzyme concentration range linearly related with the initial velocity

To determine the optimal AChE concentration required to establish linear product formation, an AChE titration time course was performed from 500 – 25 pM. The final reaction mixture (10 μ L) also contained 100 mM Tris HCl, 200 μ M ACh and 0.1% DMSO (to mimic compound addition). The reaction mixture was incubated at room temperature for 11 minutes, with regular quenching taking place every minute with 40 μ L of 1% formic acid in LC-MS grade water.

Mass spectrometry

Multiple reaction monitoring (MRM) data for all experiments were collected in positive polarity using the SCIEX Triple Quad 6500+ mass spectrometer using the parameters outlined in Table 2. Key ion source parameters have been outlined in Table 3.

Table 2: MRM parameters for ACh and Ch

Parameter	Acetylcholine	Choline
Q1/Q3 (m/z)	142.210/87.049	104.200/60.053
Dwell time	45	45
DP	25	50
EP	10	10
CE	20	24
CXP	5	23

Table 3. Source and gas conditions

Parameter	Setting
Curtain gas	30 psi
lon source gas 1	90 psi
lon source gas 2	60 psi
CAD gas	12
lon spray voltage	5000 V
Source temperature	300 °C

Acoustic Droplet Ejection method

The choice of carrier solvent was based on the solvent composition of the existing MS assay. It uses a high percentage of acetonitrile because its low viscosity allows for a higher flow rate on the Echo MS system. The final carrier solvent composition for this assay was 70% acetonitrile with 0.1% formic acid in LC-MS grade water. A faster flow rate allowed peaks produced from ejections to be narrower and to return to baseline faster, reducing the need for a long delay time between ejections. The flow rate of the carrier solvent was optimized for a specific electrode, with manual iterative testing to maintain a suitable peak shape. For these data, a flow rate of 650 μ L/min was optimal for the electrode used with a 2.5 nL ejection volume with a 1500 ms delay time between ejections. The small ejection volume provided sufficient response for both analytes with good reproducibility.

Analyte sensitivity and instrument carryover

The Echo MS system demonstrated good linearity over a wide range of concentrations (Figure 1), with the LoD for both analytes determined to be ~23 nM with a 2.5 nL ejection. Calibration curve data were fitted using linear regression with 1/xweighting, and correlation coefficients (R²) were all above 0.99. The calibration curves were run in analytical triplicate to demonstrate system reproducibility, which has been illustrated



by SD error bars in Figure 2. It was also demonstrated that there was no sample carryover using this method, reducing the risk of false positive responses and removing the need for extra washes between samples (data not shown).



Figure 2. ACh and Ch calibration curves. The LoD for each analyte was determined to be ~23 nM, with a linear dynamic range reaching 30 μM

Biochemical assay development and validation

All assay development experiments were carried out in biological duplicate. The kinetic parameters for AChE were determined under initial rate conditions. Figure 3 shows the saturation curve generated for the ACh substrate, where the data has been plotted as rate (μ M/min) vs time (min). Results were plotted in GraphPad Prism version 5.0.4, and the apparent K_M for AChE was calculated using the Michaelis-Menten analysis parameters within this software. K_M was determined to be 214.2 μ M.

A final substrate concentration of 100 μ M was selected for the screening assay as it was below K_M (where the reaction follows linear kinetics) and to save on reagent.



Figure 3. Saturation curve for ACh providing substrate K_{M} of 214.2 μM

Figure 4 illustrates a time course with percent turnover of ACh to Ch at different concentrations of AChE. The reaction is initially linear for approximately 10 minutes, after which it gradually plateaus as the substrate is depleted. Only the linear portion of each reaction has been plotted. A final enzyme concentration of 125 pM and an incubation time of 8 minutes were selected for the screening assay to give an approximate linear substrate turnover of 10 - 15%.



Figure 4. AChE enzyme titration time course illustrating turnover of ACh to Ch as percent conversion

To validate the final assay conditions, a set of DMSO plates were screened on the Echo MS system. To monitor assay robustness, a Z' value was calculated from each plate, using the mean and deviation of the positive and negative controls. All plates exceeded the criteria of 0.4 for this metric, averaging values \geq 0.6. Furthermore, repeat ejections of the same plate on the Echo MS system achieved the same Z' values, indicating high levels of reproducibility on this platform (data not shown).

Conclusions

- The Echo MS system produced highly sensitive and reproducible results for both standard curves and biochemical assay development experiments
- Method development for the Echo MS system was highly efficient; low sampling volume requirements for optimization and no need to implement multiple solvent systems or sample clean-up prior to MS ejection
- Quick analysis time (<2 seconds per sample) and lack of carryover on Echo MS system reduced overall plate analysis time to 10 minutes



References

- S. C. Z. R. P. Taylor, Acetylcholinesterase, Academic Press, 2009, pp. 5-7.
- [2] E. Moczydlowski, "SYNAPTIC TRANSMISSION AND THE NEUROMUSCULAR JUNCTION," in Medical Physiology, 2009.
- [3] L. A. Z. J. S. M. X. M. Li S, "Acetylcholinesterase Inhibition Assavs for Hiah-Throuahput Screenina."

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to https://sciex.com/diagnostic. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

© 2023 DH Tech. Dev. Pte. Ltd. MKT-27928



Headquarters 500 Old Connecticut Path | Framingham, MA 01701 USA Phone 508-383-7700 sciex.com International Sales For our office locations please call the division headquarters or refer to our website at sciex.com/offices